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ABSTRACT
Objective To determine the trade-off between the
sensitivity and the specificity for high grade cervical
intraepithelial neoplasia at hybrid capture 2 cut-off
values above the standard ≥1 relative light units/cut-off
level (rlu/co).
Design Systematic review.
Data sources PubMed.
Study selection Randomised controlled trials in primary
cervical screening using hybrid capture 2 testing in the
intervention arms. Articles published until August 2010
were included if the numbers of women with positive test
results and with cervical intraepithelial neoplasia were
stratified by hybrid capture 2 cut-off levels.
Participants Women in the baseline screening rounds of
the trials.
Interventions Hybrid capture 2 screening in the baseline
round including the diagnostic follow-up as practised in
the randomised controlled trials and as reported by
hybrid capture 2 cut-off values.
ResultsOwingtoheterogeneityinthetrials,meta-analysis
wasnotpossible.Includingcut-offvaluesupto≥10rlu/co,
25 observation points were available for analysis. The
relative sensitivity for cervical intraepithelial neoplasia
grade III or higher at cut-off levels of ≥2, ≥4o r≥5, and
≥10rlu/cocomparedwithacut-offlevelof≥1rlu/covaried
bytrial, but at their lowest theywere 0.97, 0.92,and 0.91,
respectively. A similar pattern was observed for cervical
intraepithelial neoplasia grade II or higher. The specificity
would increase by at least 1%, 2%, and 3%, respectively,
so that up to 24%, 39%, and 53%, of positive hybrid
capture 2 test results not associated with high grade
neoplasia could be avoided. Only two outliers existed to
this general pattern.
Conclusions Although the data were derived from the
baseline screening rounds only, the decrease in the
sensitivityforhighgradecervicalintraepithelialneoplasia
using a hybrid capture 2 cut-off level between ≥2 rlu/co
and ≥10 rlu/co seemed acceptable given the
international recommendations for testing for human
papillomavirus DNA in cervical screening, which require
90% or more sensitivity for cervical intraepithelial
neoplasiagradeIIorhighercomparedwithhybridcapture
2a t≥1 rlu/co. The data suggest that the hybrid capture 2
cut-off level could be increased in primary screening; this
seems reasonably safe and is significantly less
burdensome for women.
INTRODUCTION
The purpose of cervical screening is to decrease the
burden of cervical cancer. Since the 1960s, cytology
based cervical screening has led to major reductions
in the incidence of cervical cancer and related
mortality.
1 The method is not highly sensitive, how-
ever,andseveralcountries,includingtheUnitedKing-
dom, are considering making the transition to human
papillomavirus based screening. Although infection
with high risk human papillomavirus is a necessary
step in the development of cervical cancer, most infec-
tionsclearspontaneously.Consequentlyadiagnosisof
an infection is on its own not adequately specific for
identification of progressive cervical intraepithelial
neoplasia.
2 This may increase the need for repeated
testing and the workload for general practitioners and
gynaecologists.
3 To maximise the benefit of testing for
human papillomavirus DNA in cervical screening, a
practical diagnostic algorithm that avoids positive
human papillomavirus findings in women with no or
inconsequential cervical intraepithelial neoplasia is
therefore warranted.
Hybridcapture2(Qiagen,Gaithersburg,Maryland)
using the threshold of ≥1 relative light units/cut off
(rlu/co) is a clinically validated US Food and Drug
Administration approved test for detection of human
papillomavirus DNA, with a high sensitivity for high
grade cervical intraepithelial neoplasia. Compared
with cytology, hybrid capture 2 has an estimated rela-
tive sensitivity for detection of cervical intraepithelial
neoplasia grade III or higher of 1.32 (95% confidence
interval 1.06 to 1.64).
4 Hybrid capture 2 detects DNA
from13humanpapillomavirusgenotypes—16,18,31,
33, 35, 39, 45, 51, 52, 56, 58, 59, and 68—of which 12
are considered to be high risk for humans and one
probablycarcinogenic.
5Recommendationsforscreen-
ing women aged 30 or more use the hybrid capture
2’s levels of sensitivity for cervical intraepithelial
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reproducibility as a standard to which new tests for
human papillomavirus DNA should be compared.
6
Toavoidpositivehybridcapture2testresultsnotasso-
ciated with neoplasia, several authors have evaluated
hybrid capture 2 screening strategies with the cut-off
level for a positive test result above the standard ≥1
rlu/co. These authors assessed the trade-offs between
a decrease in the sensitivity, measured as the detection
of cervical intraepithelial neoplasia, and an improve-
ment in the specificity, measured as the test’s positive
predictive value. For example, using the hybrid cap-
ture 2 with a cut-off level of ≥1 rlu/co among women
aged 35 to 60 in the combined Italian phases 1 and 2
randomisedcontrolledtrials,thesensitivityforcervical
intraepithelial neoplasia grade III or higher was signif-
icantly increased compared with cytology: relative
sensitivity 1.52 (95% confidence interval 1.06 to
2.19). The positive predictive value was significantly
lower:relativepositivepredictivevalue0.63(95%con-
fidence interval 0.44 to 0.89). Using the cut-off level of
≥2 rlu/co, the relative sensitivity was similar, at 1.50
(1.04 to 2.16), whereas the relative positive predictive
value increased to 0.81 (0.56 to 1.15).
7 Similar studies
have been undertaken, using data from other rando-
mised controlled trials.
8-10
The studies have not produced a unanimous answer
onwhetherandtowhatextentthecut-offlevelusingthe
hybrid capture 2 could be increased. This may be
related to several methodological factors. Firstly, some
studies defined a positive test result asa referral for col-
poscopy, whereas others accounted for all women
recommended for follow-up.
3 These differences in the
definitionofapositivescreeningtestresultmakeacom-
parison acrossstudies difficult. Secondly, the outcomes
at increased hybrid capture 2 thresholds were typically
comparedwiththeoutcomesofcytologyscreening,and
as the sensitivity of cytology varies among laboratories
thistypeofevaluationmaynotallowageneralisedcon-
clusionontheoptimalcut-offlevelusinghybridcapture
2.Finally,severalstudiesobservedscreeningoutcomes
at a single increased hybrid capture 2 cut-off level (for
example, ≥2r l u / c o )
78rather than across a wider range.
We systematically determined the trade-offs between
the sensitivity and the specificity for detection of cervi-
cal intraepithelial neoplasia for hybrid capture 2 at a
rangeofincreasedcut-offlevelscomparedwiththestan-
dard ≥1 rlu/co. We focused on published data derived
frombaselinescreeningroundsoftherandomisedcon-
trolled trials using hybrid capture 2 in primary cervical
screening because these population based data have
been in the forefront of the currently ongoing discus-
sions on the future of cervical screening. In contrast
with previous studies, we used standard methods to
ensure that the outcomes could be compared.
METHODS
WeusedPubMedtosearchfordatapublisheduntilthe
end of August 2010 deriving from randomised con-
trolled trials using tests for the detection of human
papillomavirus DNA in primary cervical screening.
To improve the sensitivity for relevant articles we
adopted a two step search strategy. The first step was
used to identify all randomised controlled trials using
human papillomavirus DNA tests in primary screen-
ing populations. The second step was used to obtain a
comprehensive overview of articles published from
the identified randomised controlled trials. For this
search we used trial acronyms if these were listed in
the randomisedcontrolledtrialregisters,
1112 otherwise
we also searched under the names of the principal
investigators, contacts for the trial, or heads of organi-
sationsrunningthetrials.
11-17Inbothstepswescreened
the retrieved abstracts to identify all potentially rele-
vant papers, for which we subsequently retrieved full
text publications. See web extra for the search strate-
gies for both steps.
Statistical analysis
Owingtovariousdifferencesinthedesignsofthetrials
18
we refrained from carrying out a traditional meta-ana-
lysisand opted fora separatepresentationofthe results
fromeachtrialinastructuredformat.Usingaprespeci-
fied table format (table 1), two researchers indepen-
dently retrieved the numbers of women included in
the trials, those with a positive hybrid capture 2 test
result, and those with histologically diagnosed cervical
intraepithelialneoplasiagradesI,II,andIIIorhigherat
each reported cut-off level and for each reported age
group. Information on follow-up procedures and on
ascertainment of cervical intraepithelial neoplasia was
also obtained during this process.
Wedefinedahybridcapture2testresultaspositiveif
any test was at or above the analysed cut-off level,
regardless of the subsequent follow-up recommenda-
tions (immediate colposcopy or repeated testing).
3 We
definedapositivetestresultnotfollowedbyadiagnosis
of the studied cervical intraepithelial neoplasia as a
false positive. If followed up properly, these women
would all have undergone repeated testing or colpo-
scopy. We calculated, by grade of cervical intra-
epithelial neoplasia, the detection rates (numbers of
women with detected neoplasia per 100000 women),
the relative sensitivity, the relative specificity, and the
relative risks of false positive test results at increased
hybrid capture 2 cut-off levels, using the number of
women with positive test results and the detection of
cervical intraepithelial neoplasia at ≥1 rlu/co as the
reference values. The 95% confidence intervals were
calculated by assuming a binomial distribution of the
studied events.
RESULTS
Thefirststepofthesearchidentified275articles(fig1).
After screening of the abstracts, 35 full text articles
were retrieved. Eleven randomised controlled trials
that used testing for human papillomavirus DNA in
primaryscreeningwereidentifiedthisway.Twoofthe
trials
1920didnotusehybridcapture2andoneincluded
a selected group of women who had not responded to
previous invitations.
21 These three trials were
excluded from further searches. For the remaining
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second step retrieved 471 articles (fig 1). The abstracts
were checked and 34 full text articles were retrieved.
For three trials, no article was found stratifying the
number of women with positive screening tests and
the number of women with detected cervical intra-
epithelial neoplasia by hybrid capture 2 cut-off level,
and from one trial these data were not stratified in
enough detail.
822-26 Finally, in five articles from four
trials the relevant outcomes were reported by hybrid
capture2cut-offlevelinthebaselineroundoftheinter-
ventionarms:onefromFinland,
10onefromtheUnited
Kingdom,
9 one from Italy (phase 2 trial),
7 and two
from Italy (phase 1 trial).
2728 Hybrid capture 2 data
from the UK trial, however, were stratified in greater
detail in a publication combining data from the inter-
ventionandcontrolarms(inthecontrolarmoftheUK
trial,theoutcomeofhybridcapture2testingwasavail-
able but concealed forthe purposeof the management
of women),
14 and we used these latter data. In none of
the trials were data from the subsequent screening
round stratified by hybrid capture 2 cut-off level. All
four trials with the relevant data were undertaken
within established organised screening programmes
andincludedpreviouslyscreenedwomenafteraninvi-
tation for screening. Taking into account the observed
losstofollow-up,ascertainmentofdiagnosesinwomen
with abnormal screening test results was complete in
all trials except for Finland, where data have not been
reported by cut-off level for women with a positive
hybrid capture 2 test result with triage cytology less
severe than low grade squamous intraepithelial neo-
plasia. The processes of obtaining reference diagnoses
varied by study and are summarised in table 2.
Proportion of women with a positive screening test result
The numbers of women with a positive test result and
the numbers of cervical intraepithelial neoplasia grade
III or higher and grade II or higher could be extracted
from all trials (table 1). The proportions of positive
hybrid capture 2 test results varied by trial but were
consistently lower in trials including only women
older than 30 (fig 2). The hybrid capture 2 test was
positive at ≥1 rlu/co in 7.1% and 5.8% of women in
the Italian phase 1 and phase 2 trials (35-60 years),
respectively, and in 8.0% in the Finnish trial
(30-60 years). The test result was positive in 13.9% of
women in the Italian phase 1 trial (25-34 years), 13.1%
in the Italian phase 2 trial (25-34 years), and 15.6% in
the UK trial (20-64 years). The proportion of women
with a positive hybrid capture 2 test decreased by
increased cut-off levels in all trials.
Relative sensitivity for cervical intraepithelial neoplasia by
hybrid capture 2 cut-off level
At a cut off of ≥1 rlu/co, the detection rates of cervical
intraepithelial neoplasia grade III or higher varied
between 119 and 1240 per 100000 screened women
(fig 2). Per 100000 women screened the detection
rates of cervical intraepithelial neoplasia grade II var-
ied between 192 and 996 and those of cervical intra-
epithelial neoplasia grade I varied between 249 and
2033,underliningthevariabilityofthestudiedpopula-
tions, the subjective nature of cervical intraepithelial
neoplasia diagnosis, and the variability in the comple-
teness of reported data. Despite the described inter-
trial variation in the detection rates of cervical intra-
epithelial neoplasia grade III or higher and grade II
or higher, similar relative sensitivities compared with
a cut-off level ≥1 rlu/co were observed when the
threshold was increased (see web extra figure).
Throughout the range of cut-off levels up to ≥10
rlu/co, the relative sensitivities for cervical intra-
epithelial neoplasia grade III or higher and for grade
II or higher were consistently at least 90% compared
with ≥1 rlu/co in all trials except one (table 3).
At cut-off level ≥2 rlu/co, the relative sensitivity for
cervical intraepithelial neoplasia grade III or higher in
the Italian phase 1 trial (35-60 years) was 0.97. The
relativesensitivityforcervicalintraepithelialneoplasia
grade II or higher in the UK trial was 0.97, and in the
Italianphase2trial(35-60years)itwas0.94.Inallother
reviewed trials the relative sensitivity for cervical
Table 1 |Randomised controlled trials with hybrid capture 2 based screening: numbers of
women with positive test results at various cut-off levels, and with detected cervical
intraepithelial neoplasia grade III or higher, grade II, and grade I
Trial (age range)
Hybrid capture
2 cut-off level
(rlu/co)
No of women
with positive
test result
Cervical intraepithelial neoplasia grade
IIIorhigher II I
Italian phase 1 (25-34)
27
≥1 836 15 39 122
≥2 730 15 39 114
≥4 664 15 37 112
≥10 575 14 35 101
Italian phase 2 (25-34)
7
≥1 907 24 44 133
≥2 796 24 43 121
≥4 703 23 43 112
≥10 615 23 41 98
UK trial (20-64)
14
≥1 3813 304 244 NA
≥2 3200 300 234 NA
≥4 2816 293 229 NA
≥10 2358 282 216 NA
Italian phase 1 (35-60)
28
≥1 1185 38 35 118
≥2 908 37 35 98
≥4 738 35 34 85
≥10 572 35 33 65
Italian phase 2 (35-60)
7
≥1 1029 35 34 103
≥2 789 35 30 82
≥4 647 33 27 68
≥10 533 29 22 54
Finnish trial (30-60)
10
≥11 4 7 5 2 2 5 5 4 6
≥21 2 2 1 2 2 5 5 4 6
≥31 1 1 0 2 2 5 5 4 4
≥5 972 21 52 44
≥10 797 20 50 42
≥50 500 18 44 31
≥250 246 8 24 25
≥1000 84 5 17 0
NA=not available.
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grade II or higher was closer to 1.
At cut-off level ≥4 rlu/co (≥5 rlu/co in the Finnish
trial), the relative sensitivity for cervical intraepithelial
neoplasia grade III or higher ranged between 0.92 in
the Italian phase 1 trial (35-60 years) and 1.00 in the
Italianphase1trial(25-34years).Therelativesensitiv-
ity for cervical intraepithelial neoplasia grade II or
higher in the Italian phase 2 trial (35-60 years) was
0.87. In other trials, the relative sensitivity for cervical
intraepithelial neoplasia grade II or higher ranged
between 0.95 (UK, Italian phase 1 (35-60 years), Fin-
land) and 0.97 (Italian phase 2, 25-34 years).
At cut-off level ≥10 rlu/co, the relative sensitivity for
cervicalintraepithelialneoplasiagradeIIIorhigherwas
the lowest in the Italian phase 2 trial (35-60 years), at
0.83. In other trials, the relative sensitivity for cervical
intraepithelial neoplasia grade III or higher varied
between 0.91 (Finland) and 0.96 (Italian phase 2,
25-34 years). The relative sensitivity for cervical intra-
epithelialneoplasiagradeIIorhigherwasagainthelow-
est in the Italian phase 2 trial (35-60 years), at 0.74,
whereas in the other trials it ranged between 0.91 (UK,
Italian phase 1 (25-34 years), Finland) and 0.94 (Italian
phase2,25-34years).Athighercut-offlevelsintheFin-
nishtrial,therelativesensitivityforanygradeofcervical
intraepithelial neoplasia decreased substantially.
The relative sensitivity for cervical intraepithelial
neoplasia grade I tended to be more substantially
decreased at increased cut-off level, although more so
inthe Italiantrialsthanin theFinnishtrial(table 3).At
cut-off level ≥4 rlu/co (≥5 rlu/co in the Finnish trial),
therelativesensitivitiesforcervicalintraepithelialneo-
plasiagradeIwere0.92and0.84intheItalianphases1
and 2 trials (25-34 years), 0.72 and 0.66 in the Italian
phases 1 and 2 trials (35-60 years), and 0.96 in the Fin-
nish trial. At cut-off level ≥10 rlu/co the relative sensi-
tivities were 0.83, 0.74, 0.55, 0.52, and 0.91,
respectively.
Relative specificity for cervical intraepithelial neoplasia by
hybrid capture 2 cut-off level
At all increased cut-off levels, the specificity for cervi-
cal intraepithelial neoplasia grade III or higher
increased significantly (table 3, web extra figure). At
cut-offlevel≥2rlu/co,thespecificityincreasedwithina
rangeof1%(Italianphase2(35-60years),andFinland)
and 3% (UK trial). At cut-off level ≥4 rlu/co (≥5 rlu/co
in Finland), the specificity increased within a range of
2%(Italianphase2,35-60years)and5%(UKtrial),and
at cut-offlevel ≥10 rlu/co it increasedwithin a range of
3% (Italian phase 2, 35-60 years) and 7% (UK trial).
Similarnumberswerefoundforcervicalintraepithelial
neoplasia grade II or higher as end point.
These gradual increases in the specificity were
reflectedintheconsiderablyreducedrisksoffalseposi-
tive hybrid capture 2 test results (fig 3). When cervical
intraepithelialneoplasiagradeIIIorhigherwasusedas
an end point, for example, the relative proportions
compared with ≥1 rlu/co at cut-off level ≥10 rlu/co
were 0.68 and 0.67 in the Italian phases 1 and 2 trials
(25-34 years), 0.59 in the UK trial, 0.47 and 0.51 in the
Italian phases 1 and 2 trials (35-60 years), and 0.53 in
theFinnishtrial.Similarresultswereobtainedforother
grades of cervical intraepithelial neoplasia (data not
shown).
DISCUSSION
Recently published international recommendations
forscreeningwomenaged30ormoreforhumanpapil-
lomavirusrequirethatnewteststodetecthumanpapil-
lomavirus DNA show at least a 90% sensitivity for
cervical intraepithelial neoplasia grade II or higher
compared with the sensitivity of hybrid capture 2 test-
ing using the cut-off level ≥1 rlu/co,
6 and according to
Kinney et al, the sensitivity of human papillomavirus
screening for cervical intraepithelial neoplasia grade
III or higher should be above 90%.
2 Our reanalysis of
the reported trial data showed that hybrid capture 2
testing using the range of increased cut-off levels
between ≥2 rlu/co and ≥10 rlu/co is able to meet
Records after duplicates removed (n=275)
Records screened (n=275)
Additional records identified
through other sources (n=0)
Records identified through
database searching (n=275)
Records excluded (n=240)
Full text articles excluded (n=8):
  Hybrid capture 2 not used (2 trials, 7 articles)
  Selected group of women (1 trial, 1 article)
Studies included in qualitative synthesis (n=27)
8 randomised controlled trials trials identified; then step 2
Screening
Full text articles assessed for eligibility (n=35)
Eligibility
Records after duplicates removed (n=471)
Records screened (n=471)
Records excluded (n=437)
Full text articles excluded (n=29):
  Screening outcomes not reported by hybrid
    capture 2 cut-off level (n=24)
  Screening outcomes not reported by hybrid
    capture 2 cut-off level in enough detail (n=5)
Screening
Full text articles assessed for eligibility (n=34)
Eligibility
Included
Studies included in qualitative synthesis
(meta-analysis) (n=5): not applicable
Included
Identification
Step 1
Additional records identified
through other sources (n=0)
Records identified through
database searching (n=471)
Identification
Step 2
Fig 1 | Study selection
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insteadof≥1rlu/co,upto3%ofcervicalintraepithelial
neoplasia grade II or higher and of grade III or higher
detectable at cut-off level ≥1 rlu/co would not be
detectedatthegivenscreen.Upto8%ofcervicalintra-
epithelial neoplasia grade II or higher and of grade III
or higher would not be detected at the given screen if
the cut-off levels ≥4o r≥5 rlu/co were used, and up to
9% if the cut-off level ≥10 rlu/co was used. The speci-
ficity of the hybrid capture 2 test was significantly
increased with increased cut-off levels, reflecting a sig-
nificantly reduced risk of false positive test results. At
cut-off level ≥10 rlu/co, this risk was reduced by about
one half among women aged 30 or more, whereas
among younger women the reduction was about one
third. The observed patterns were consistent across
trials, with the only exception being the Italian phase
2trialforwomenaged35to60.Inthistrial,17%ofthe
cervical intraepithelial neoplasia grade III or higher
would be missed at cut-off level ≥10 rlu/co. Owing to
the relatively low number of cervical intraepithelial
neoplasia grade II or higher and of grade III or higher
reported from most trials, the calculated 95% confi-
dence intervals for relative sensitivities were wide.
Limitations of the study
No reported data sufficiently stratified by hybrid
capture2cut-offlevelcouldbeidentifiedfromfourran-
domised controlled trials, of which two were underta-
ken in previously unscreened women,
2526 one was not
undertakenwithinanorganisedscreeningprogramme,
8
and one has not yet completed its recruitment.
22 The
outcomes presented in this systematic review may
therefore not be generalisable to settings with
opportunistic screening and settings with previously
unscreened women. Some of the data from the four
trials included in this systematic review have been
incompletely reported. For instance, data on lesions
detected during the extended follow-up in the two Ita-
lian trials
29 have not been reported by baseline cut-off
levels, and data on lesions detected during follow-up
with repeated testing of women with triage cytology
less severe than low grade squamous intraepithelial
lesions have not been reported by cut-off level from
theFinnishtrial.
30Itcouldbearguedthatinthereported
data from the Finnish trial, the detection of cervical
intraepithelial neoplasia grade I was particularly low
because only women positive for human papilloma-
virus and with at least low grade squamous intra-
epithelial neoplasia on cytology were referred for
colposcopy.
Detection of cervical intraepithelial neoplasia
depends on the follow-up procedures for women who
were positive at hybrid capture 2 cut-off level ≥1
rlu/co, and these procedures varied by trial (table 2).
In the Italian phase 2 trial, all of these women were
immediately referred for colposcopy, whereas in the
Italian phase 1 trial they were immediately referred
for colposcopy only if they were older than 34 or had
abnormal cytology, in the Finnish trial if the cytology
was low grade squamous intraepithelial neoplasia or
worse, and in the UK trial if the cytology was at least
moderately abnormal. In trials with reported data,
more than 90% of the immediately referred women
had colposcopy. Women with a positive hybrid cap-
ture 2 test result not immediately referred for colpo-
scopy were recommended to undergo repeated
testing in six to 12 months, and only 55% in the UK
Table 2 |Reported data on follow-up procedures from randomised controlled trials
Trial Acronym
Age range
(years)
No in intervention
arm
Follow-up recommendations after positive
hybrid capture 2 test result (≥1 rlu/co)
Compliance with follow-up
recommendations Reported histology
Italian phase 1
27 NTCC 1 25-34 6002 Cytologynormal:repeattestingat12months;
atypical squamous cells of undetermined
significance or worse: colposcopy
Cytology normal: 62%; atypical
squamous cells of undetermined
significance or worse: 94%
Consensus diagnosis ≤1y e a ro f
referral for colposcopy (immediate
or after repeated testing)
Italian phase 1
27 NTCC 2 25-34 6937 Colposcopy 94% Consensus diagnosis ≤1y e a ro f
referral for colposcopy (immediate
or after repeated testing)
UK trial
14 ARTISTIC 20-64 24 510* Intervention arm: cytology normal: repeat
testing at 12 months; borderline or mildly
abnormal: repeat testing at six months;
moderately abnormal or worse: colposcopy.
Control arm: borderline or mildly abnormal:
repeat testing at six months; moderately
abnormal or worse: colposcopy
Intervention arm: cytology normal:
55%. Other: NA
Worst diagnosis in ≤30 months of
abnormal round 1 sample
Italian phase 1
28 NTCC 1 35-60 16 706 Colposcopy 93% Consensus diagnosis ≤1y e a ro f
referral for colposcopy (immediate
or after repeated testing)
Italian phase 2
7 NTCC 2 35-60 17 724 Colposcopy 93% Consensus diagnosis ≤1y e a ro f
referral for colposcopy (immediate
or after repeated testing)
Finnish trial
10 NA 30-60 18 438 Cytologynormaloratypicalsquamouscellsof
undetermined significance: repeat testing at
12 months; low grade squamous
intraepithelial lesions† or worse: colposcopy
NA NA
NA = not available.
*Intervention and control arm combined.
†Histology not reported for women with cytology less severe than low grade squamous intraepithelial lesions.
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repeated test and a colposcopy if the repeated test
result was positive. Despite this variability in the fol-
low-up strategies across trials, the trade-offs between
the indicators of sensitivity and specificity at increased
hybrid capture 2 cut-off levels were similar.
It should be taken into account that women in the
interventionarmsofthetrialswerepredominantlyman-
aged according to the hybrid capture 2 cut-off level ≥1
rlu/co. Thus, these data did not allow for a direct com-
parison of the long term negative predictive values at
different cut-off levels. The excellent negative predic-
tive values found at cut-off level ≥1 rlu/co suggested
that the screening intervals could be extended from
the current three to five years with cytology to 6 to 7.
5 years using human papillomavirus DNA testing.
3132
Theoretically, increasing the cut-off level may not
allow precisely the same extension of the screening
interval. Many cervical intraepithelial neoplasia grades
III and II though do not progress to cervical cancer.
When they do, the progression is gradual and on aver-
age takes more than 10 years.
33-35 The increased cut-off
level is therefore not expected to substantially decrease
theeffectivenessofhybridcapture2.Similarprecaution
needs to be taken when the sensitivity of new human
papillomavirus DNA tests will be compared with
hybrid capture 2 using the published guidelines.
6
Other studies
Screening outcomes stratified by hybrid capture 2 cut-
off level have been reported also from several split
sample studies in which women were screened with
both hybrid capture 2 and cytology. In general, these
studiescorroboratedthefindingsfromtherandomised
controlled trials. For example, among the 10358
women aged 30 to 60 in the HART study, 67 had a
diagnosis of cervical intraepithelial neoplasia grade
IIIorhigherafterapositivehybridcapture2testresult
using the cut-off level ≥1 rlu/co. In 93% of these 67
women (62/67; 95% confidence interval 83% to
98%), the hybrid capture 2 test result was positive at
≥10 rlu/co. At this cut-off level, 40% fewer women
had a false positive test result compared with a cut-off
level ≥1 rlu/co (428/717; 37% to 44%).
36 In a French
study of 7932 females screened aged 15 to 76, 96% of
cervicalintraepithelialneoplasiagradeIIorhigherwas
detected witha hybrid capture2 cut-off level ≥3 rlu/co
(124/129; 91% to 99%), although at the cut-off level
≥10 rlu/co this proportion decreased to 88% (114/
129; 82% to 93%).
37 In 1999 Finnish females aged 15
to86referredforvariousgynaecologicaldisorders,the
relativesensitivityforcervicalintraepithelialneoplasia
grade III or higher was 0.86 (19/22; 0.65 to 0.97) and
forgradeIIorhigheritwas0.93(42/45;0.82to0.99)at
a cut-off level ≥5 rlu/co compared with ≥1 rlu/co.
38
Among9057previouslyunscreenedwomenaged30
to 54 in rural China, 134 had a diagnosis of cervical
intraepithelial neoplasia grade III or higher associated
with a hybrid capture 2 positive test result at cut-off
level≥1rlu/coand125atcut-offlevel≥10rlu/co(rela-
tive sensitivity 0.93, 95% confidence interval 0.88 to
0.97). Although the relative sensitivity was slightly
decreased (0.88) when adjustment was applied to
account for the differences among the participating
centres and verification bias, the authors concluded
that using hybrid capture 2 testing with a cut-off level
≥10 rlu/co “might be the most appropriate” screening
strategy for areas with basic screening infrastructure
that does not allow frequent screening.
39
Recently, detailed results for a range of hybrid cap-
ture 2 cut-off levels were presented from a Dutch
VUSA-screen cohort study of 25871 women aged 30
to 60 screened with both hybrid capture 2 and
cytology.
40 In this study, the relative sensitivity for
high grade cervical intraepithelial neoplasia and the
relativerisksoffalsepositivetestresultswithincreased
hybridcapture2cut-offlevelswerecomparedwiththe
outcomesofcytologyscreening.Onlywomenreferred
for colposcopy were taken into account in the calcula-
tion of the risk of false positive test results. This study
could not identify any increased hybrid capture 2 cut-
offlevelatwhichthecolposcopyreferralratewouldbe
similar to that in cytology screening without at the
sametimesubstantiallydecreasingthetest’ssensitivity
for high grade cervical intraepithelial neoplasia. The
authors consequently proposed to keep the ≥1 rlu/co
cut-off level. We recalculated the VUSA-screen data
using the hybrid capture 2 test with a cut-off level ≥1
rlu/co as a reference, and accounting for all positive
screening test results in the calculation. At a cut-off
level ≥10 rlu/co, the relative sensitivity for cervical
intraepithelial neoplasia grade III or higher was 0.90
(131/146; 95% confidence interval 0.84 to 0.94) com-
pared with cut-off level ≥1 rlu/co, and the correspond-
ing relative risk of false positive test results was 0.64
(746/1157; 0.62 to 0.67). The relative sensitivity for
cervical intraepithelial neoplasia grade II or higher
was0.89(203/227;0.85to0.93)andthecorresponding
Hybrid capture 2 cut-off levels (rlu/co)
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Fig 2 | Percentage of women with positive hybrid capture 2 test results, and detection rates of
cervical intraepithelial neoplasia grade III or higher (CIN III+) per 1000 women screened, by
hybrid capture 2 cut-off level in intervention arms of reviewed randomised controlled trials
(intervention+control arm in UK trial)
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1076; 0.60 to 0.65). Thus, the VUSA-screen data were
in line with the data from the analysed randomised
controlledtrials,andinfactsupportusinganincreased
hybrid capture 2 cut-off level in screening.
Effect on cervical intraepithelial neoplasia treatment and
the psychosocial burden of screening
If the cut-off level was increased from ≥1 rlu/co to ≥10
rlu/co, up to 18 fewer women with cervical intra-
epithelial neoplasia grade III or higher per 100000
screened women would be diagnosed and treated at
the given screen in part of the Italian trials and in the
Finnishtrials.Thisnumberwas34intheItalianphase2
trial (35-60 years) and 90 in the UK trial, although in
the case of the UK trial this still represented less than
10% of all detected cervical intraepithelial neoplasia
grade III or higher at ≥1 rlu/co. The rare prevalent
cancercasesatagivenscreeningroundmay,however,
be at risk of being missed at any cut-off point.
41
Even in women over 30, the use of human papillo-
mavirus DNA tests would in many countries double
the number of women with a positive screening test
result compared with cytology.
782028 To help manage
this increase, several authors have focused on finding
optimal triage procedures to avoid excess referral for
colposcopyandexcessdiagnoses,particularlyofcervi-
cal intraepithelial neoplasia grade II.
742 This is war-
ranted, as colposcopy tends to be relatively expensive
and induces anxiety.
43 Furthermore, cervical intra-
epithelial neoplasia grade II is often regressive
4445 but
nevertheless usually recommended for treatment that
may be associated with severe obstetric outcomes.
46
Women with positive human papillomavirus test
results who are not immediately referred for colpo-
scopyarenormallyrecommendedforrepeatedtesting.
These repeated tests increase the workload of general
practitioners or gynaecologists and affect women’s
quality of life.
47-49 The need for repeated tests could
be substantially decreased by using an increased cut-
offpoint.Theriskofnotdetectingasmallproportionof
cervical intraepithelial neoplasia grade III at a given
screening round should thus be interpreted in the
light of substantially diminished overdetection of
harmless human papillomavirus infections in healthy
women. The frequency of such infections can be well
Table 3 |Relative sensitivity, relative specificity, and relative risks of false positive test results, by hybrid capture 2 cut-off level
Trial (age range)
Hybrid capture 2
cut-offlevel(rlu/co)
Cervical intraepithelial neoplasia
grade III or higher
Cervical intraepithelial neoplasia
grade II or higher
Cervical
intraepithelial
neoplasia grade I
Relative sensitivity
(95% CI)
Relative specificity
(95% CI)
Relative risk of
false-positive tests
(95% CI)
Relative sensitivity
(95% CI)
Relative specificity
(95% CI)
Relative sensitivity
(95% CI)
Italian phase 1
(25-34)
≥1 111 11 1
≥2 1.00 (0.78 to 1.00) 1.02 (1.02 to 1.02) 0.87 (0.85 to 0.89) 1.00 (0.93 to 1.00) 1.02 (1.02 to 1.02) 0.93 (0.87 to 0.97)
≥4 1.00 (0.78 to 1.00) 1.03 (1.03 to 1.04) 0.79 (0.76 to 0.82) 0.96 (0.87 to 1.00) 1.03 (1.03 to 1.04) 0.92 (0.85 to 0.96)
≥10 0.93 (0.68 to 1.00) 1.05 (1.04 to 1.06) 0.68 (0.65 to 0.72) 0.91 (0.80 to 0.97) 1.05 (1.04 to 1.06) 0.83 (0.75 to 0.89)
Italian phase 2
(25-34)
≥1 111 11 1
≥2 1.00 (0.88 to 1.00) 1.02 (1.02 to 1.02) 0.87 (0.85 to 0.90) 0.99 (0.92 to 1.00) 1.02 (1.01 to 1.02) 0.91 (0.85 to 0.95)
≥4 0.96 (0.79 to 1.00) 1.03 (1.03 to 1.04) 0.77 (0.74 to 0.80) 0.97 (0.90 to 1.00) 1.03 (1.03 to 1.04) 0.84 (0.77 to 0.90)
≥10 0.96 (0.79 to 1.00) 1.05 (1.04 to 1.05) 0.67 (0.64 to 0.70) 0.94 (0.86 to 0.98) 1.05 (1.04 to 1.05) 0.74 (0.65 to 0.81)
UK trial
(20-64)
≥1 111 11 N A
≥2 0.99 (0.97 to 1.00) 1.03 (1.03 to 1.03) 0.83 (0.81 to 0.84) 0.97 (0.96 to 0.99) 1.03 (1.03 to 1.03) NA
≥4 0.96 (0.94 to 0.98) 1.05 (1.04 to 1.05) 0.72 (0.70 to 0.73) 0.95 (0.93 to 0.97) 1.05 (1.04 to 1.05) NA
≥10 0.93 (0.89 to 0.95) 1.07 (1.07 to 1.07) 0.59 (0.58 to 0.61) 0.91 (0.88 to 0.93) 1.07 (1.06 to 1.07) NA
Italian phase 1
(35-60)
≥1 111 11 1
≥2 0.97 (0.86 to 1.00) 1.02 (1.02 to 1.02) 0.76 (0.73 to 0.78) 0.99 (0.93 to 1.00) 1.02 (1.02 to 1.02) 0.83 (0.75 to 0.89)
≥4 0.92 (0.79 to 0.98) 1.03 (1.03 to 1.03) 0.61 (0.58 to 0.64) 0.95 (0.87 to 0.98) 1.03 (1.03 to 1.03) 0.72 (0.63 to 0.80)
≥10 0.92 (0.79 to 0.98) 1.04 (1.04 to 1.04) 0.47 (0.44 to 0.50) 0.93 (0.85 to 0.98) 1.04 (1.04 to 1.04) 0.55 (0.46 to 0.64)
Italian phase 2
(35-60)
≥1 111 11 1
≥2 1.00 (0.90 to 1.00) 1.01 (1.01 to 1.02) 0.76 (0.73 to 0.78) 0.94 (0.86 to 0.98) 1.01 (1.01 to 1.02) 0.80 (0.71 to 0.87)
≥4 0.94 (0.81 to 0.99) 1.02 (1.02 to 1.03) 0.62 (0.59 to 0.65) 0.87 (0.77 to 0.94) 1.02 (1.02 to 1.02) 0.66 (0.56 to 0.75)
≥10 0.83 (0.66 to 0.93) 1.03 (1.03 to 1.03) 0.51 (0.48 to 0.54) 0.74 (0.62 to 0.84) 1.03 (1.03 to 1.03) 0.52 (0.42 to 0.62)
Finnish trial
(30-60)
≥1 111 11 1
≥2 1.00 (0.85 to 1.00) 1.01 (1.01 to 1.02) 0.83 (0.80 to 0.84) 1.00 (0.95 to 1.00) 1.01 (1.01 to 1.02) 1.00 (0.92 to 1.00)
≥3 1.00 (0.85 to 1.00) 1.02 (1.02 to 1.02) 0.75 (0.73 to 0.77) 1.00 (0.95 to 1.00) 1.02 (1.02 to 1.02) 0.96 (0.85 to 0.99)
≥5 0.95 (0.77 to 1.00) 1.03 (1.03 to 1.03) 0.65 (0.63 to 0.68) 0.95 (0.87 to 0.99) 1.03 (1.03 to 1.03) 0.96 (0.85 to 0.99)
≥10 0.91 (0.71 to 0.99) 1.04 (1.04 to 1.04) 0.53 (0.51 to 0.56) 0.91 (0.82 to 0.96) 1.04 (1.04 to 1.04) 0.91 (0.79 to 0.98)
≥50 0.82 (0.60 to 0.95) 1.06 (1.05 to 1.06) 0.33 (0.31 to 0.36) 0.81 (0.70 to 0.89) 1.06 (1.05 to 1.06) 0.67 (0.52 to 0.80)
≥250 0.36 (0.17 to 0.59) 1.07 (1.07 to 1.08) 0.16 (0.15 to 0.18) 0.42 (0.30 to 0.53) 1.07 (1.07 to 1.07) 0.54 (0.39 to 0.69)
≥1000 0.23 (0.08 to 0.45) 1.08 (1.08 to 1.09) 0.05 (0.04 to 0.07) 0.29 (0.19 to 0.40) 1.08 (1.07 to 1.08) 0.00 (0.00 to 0.08)
NA=not available.
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screened women, about 1500 fewer healthy women
would have a false positive test result on screening
using hybrid capture 2 and remain in follow-up at cut-
off level ≥2 rlu/co compared with the cut-off level ≥1
rlu/co. Likewise, about 3000 and 4000 fewer healthy
women would have a false positive hybrid capture 2
test result if the cut-off level was increased to ≥4( ≥5)
rlu/co and ≥10 rlu/co, respectively. These numbers
were consistent across the reported trial data. In most
settings, treatment of cervical intraepithelial neoplasia
grade I is not recommended,
50 and another benefit of
anincreasedcut-offlevelforthehybridcapture2testis
therefore the reduced detection of cervical intra-
epithelial neoplasia grade I. Using the cut-off level
≥10 rlu/co in both Italian trials, for example, cervical
intraepithelial neoplasia grade I diagnoses could be
avoided in at least 300 per 100000 screened women.
Conclusion
Increasingthecut-offlevelforapositivehybridcapture
2 test result above the standard ≥1 rlu/co is associated
with a risk of not detecting some high grade cervical
intraepithelial neoplasia as early as it would otherwise
have been possible. The trade-offs between decreased
sensitivity and increased specificity resulting from
increasing the hybrid capture 2 cut-off level, however,
seem acceptable according to the recent international
recommendations on human papillomavirus DNA
testing,andbothyoungerandolderwomenwouldben-
efit from this change. In the reported data from most
reviewed trials, the relative sensitivity at increased cut-
off levels for cervical intraepithelial neoplasia grade II
orhigherandforgradeIIIorhigherwouldstillbe90%
or more compared with ≥1 rlu/co. This was the case
even when the hybrid capture 2 cut-off level was
increased to≥10rlu/co.Atthislevel,the improvement
inthespecificityledtoabouthalfasmanywomenaged
30 or more and about one third fewer younger women
with a false positive hybrid capture 2 test result com-
pared with the standard cut-off level.
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